Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DSGN

DSGN - Design Therapeutics, Inc. Stock Price, Fair Value and News

$10.11-0.48 (-4.53%)
Market Closed

Price Targets

DSGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DSGN Price Action

Last 7 days

5.9%

Last 30 days

3.3%

Last 90 days

54.8%

Trailing 12 Months

101.8%

DSGN RSI Chart

DSGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DSGN Valuation

Market Cap

575.9M

Price/Earnings (Trailing)

-8.54

Price/Sales (Trailing)

1.7K

Price/Free Cashflow

-10.99

DSGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

DSGN Fundamentals

DSGN Revenue

Revenue (TTM)

226.0K

DSGN Earnings

Earnings (TTM)

-67.4M

Earnings Growth (Yr)

-30.36%

Earnings Growth (Qtr)

10.93%

DSGN Profitability

Return on Equity

-33.77%

Return on Assets

-31.85%

Free Cashflow Yield

-9.1%

DSGN Investor Care

Shares Dilution (1Y)

0.61%

Diluted EPS (TTM)

-1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2020000226.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Design Therapeutics, Inc.

DSGN
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
 CEO
 WEBSITEdesigntx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES68

Design Therapeutics, Inc. Frequently Asked Questions

DSGN is the stock ticker symbol of Design Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Design Therapeutics, Inc. is 575.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DSGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether DSGN is over valued or under valued. Whether Design Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Design Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DSGN.

As of Wed Jan 28 2026, DSGN's PE ratio (Price to Earnings) is -8.54 and Price to Sales (PS) ratio is 1.65 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DSGN PE ratio will change depending on the future growth rate expectations of investors.